Proteostasis Therapeutics Presents Data at Multiple Scientific Conferences Highlighting Novel Approach to Neurodegenerative Diseases and Cystic Fibrosis

Proteostasis Therapeutics Presents Data at Multiple Scientific Conferences Highlighting Novel Approach to Neurodegenerative Diseases and Cystic Fibrosis

<0> Stern Investor Relations, Inc.Lilian Stern, 212-362-1200 </0>

Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that company scientists, founders and co-founders made the following presentations at scientific conferences in the last month highlighting progress with the Company’s lead programs and the potential of its approach to developing disease modifying therapeutics:

“These data further demonstrate our Company’s commitment to developing novel therapeutics for neurodegenerative and orphan diseases and also show the promise of a drug discovery and development approach based on our Proteostasis Network Platform. We look forward to advancing our most promising chemical series to lead optimization this year and providing updates on our programmatic progress as we approach the clinic,” stated Peter Reinhart, President and Chief Scientific Officer of Proteostasis Therapeutics.

Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases. The Company’s lead programs in Cystic Fibrosis (CF) and protein aggregation disorders such as Parkinson’s disease modulate protein chaperone and proteasomal degradation pathways within the cell. These pathways are part of the cellular ‘quality control’ machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance. By enhancing the function and capacity of the PN, the Company’s product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. For more information, please visit .

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.